Stay updated on CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial
Sign up to get notified when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.

Latest updates to the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check32 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check61 days agoChange DetectedThe page has updated its core content to include AbbVie and its associated dates, while removing references to Cerevel Therapeutics and Julie Adams.SummaryDifference1%
- Check75 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed trial descriptions and inclusion criteria for a schizophrenia study, while retaining some key terms and a revision update.SummaryDifference21%
Stay in the know with updates to CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.